The American company Biogen Idec Inc commenced clinical trials of a new drug for Alzheimer's disease. The action of the drug is to slow the decline of cognitive abilities and in reducing the threat of protein in the brain in patients with early and moderate forms of the disease.
Testing of a new product passed for 166 volunteers, informs Reuters. They were divided into 5 groups. 1st taking the placebo, and the other 4 had used the product in different quantities from small to large doses.
It was found that the product in patients started to get rid of amyloid deposits and the effects depended on the number of medications - the larger the dose, the stronger the treatment. With all this 1st positive results from taking substances were identified after 26 weeks - specifically at this stage the concentration of sediments began to change. In spite of this, very high doses are dangerous for the body. It was discovered that they are given the opportunity to lead the brain to swell in the presence of patients with certain genetic mutations.
During the test, a product of the volunteers was assessed cognitive ability. In the group receiving placebo, the results were significantly lower compared to those patients who took the product. This confirms the impact of the medical drug in the treatment of Alzheimer's disease. With all this research will continue for another couple of years. Thus if all studies are useful, the drug can enter the market no earlier than 2020.
The global incidence of Alzheimers is about 26.6 million people. With all this, according to the monitoring scientists, by 2050 their number may increase by 4 times.
As wrote earlier Days.Roux, American scientists came up with a unique methodology for the destruction of amyloid plaques that cause Alzheimer's disease. A new method of treatment was tested on mice and is able to prevent damage to the memory and nerve cells in the brain, which is characteristic for this disease.
sections: Society, World News |
Russian News
[View all comments]
[Print]
